Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cholestyramine for HBV-positive cirrhosis
ChiCTR2200058110Phase 3Not yet recruiting
- Sponsor
- Department of Gastroenterology, Clinical medical college and the first affiliated hospital of Chengdu medical college
- Start
- Apr 2022
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of cholestyramine in Cirrhosis and Chronic Hepatitis B (CHB) (2 arms), sponsored by Department of Gastroenterology, Clinical medical college and the first affiliated hospital of Chengdu medical college. Primary endpoint: Serum endotoxin. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
cholestyramine
03
Conditions
CirrhosisChronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2200058110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058110.